PURPOSE: An inhaling type powder formulation for preventing or treating NMDA receptor function degradation related diseases is provided to effective and safe for promoting growth by identical amount of administration.CONSTITUTION: An inhaling type powder formulation for preventing or treating NMDA receptor function degradation related diseases includes growth hormone as an active component. The NMDA receptor function degradation related diseases include schizophrenia induced symptoms including dementia, Alzheimers disease, schizophrenia, senescence related reduction of learning and memory, drug induced-NMDA receptor function degradation, NMDA antagonist-induced mental disease symptoms-or cognition disorder, Huntington`s disease or chronic alcoholism. The inhaling type powder formulation additionally includes pharmaceutically acceptable excipient. The pharmaceutically acceptable excipient includes monosaccharide such as glucose and arabinose disaccharides such as lactose saccharose and maltose polysaccharides such as sorbitol, mannitol and xylitol salt such as sodium chloride and calcium carbonate calcium bicarbonate amino acid peptide: polymers: lipid: or a mixture thereof. The inhaling type powder formulation includes growth hormone, lactose and dipalmitoyl phosphatidylcholine(DPPC).COPYRIGHT KIPO 2013[Reference numerals] (AA) Relative quantification (BB) Counter group powder (CC) Saline solutionNMDA 수용체 기능저하-관련 질환을 예방 또는 치료하기 위한 흡입형 분말 제제의 용도 성장 호르몬(GH)을 포함하는 치료학적으로 유효한 양의 흡입형 분말 제제를 이를 필요로 하는 대상에게 투여하는 것을 포함하는, 상기 대상에서 NMDA 수용체 기능저하-관련 질환을 예방 또는 치료하는 방법 및 활성성분으로서 GH를 포함하는 NMDA 수용체 기능저하-관련 질환의 예방 또는 치료용 흡입형 분말 제제를 제공한다.
